Cocrystal Pharma : reimagine Health Research Symposium Presentation

reImagine HEALTH

Intervention and Prevention Symposium

Application of Structure-Based Drug Design Platform Technology

For Developing Broad Spectrum

COVID-19, Influenza, and HCV Antivirals

Sam Lee, Ph.D.

January 21, 2021

NASDAQ: COCP

Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding expected results of our collaboration with Merck Sharp & Dohme Corp. ("Merck"), including the anticipated characteristics of the drug candidates developed as the result of this collaboration, expected funding by Merck of future research, development and commercialization of products derived from such collaboration, and the expected future payments and royalties in connection with the collaboration; the expected progress in developing a compound for the effective treatment and prevention of COVID-19 infections and the anticipated timing of achieving the value-driving milestones, including achieving pre-IND status and development of additional COVID-19 inhibitors with novel mechanism of action in 2021; the expected progress of our Influenza A program, including the initiation of Phase 1 study in Q3 2021; the expected synergetic effects of CC-42344 with approved Influenza antivirals; the expected progress of our HCV program, including future partnership for further development; the expected progress of our norovirus program and the anticipated timing of achieving the value-driving milestones, including completion of a proof-of-concept animal study in H1 2021; and our estimates with respect to market opportunities and development pipeline. Forward-looking statements are prefaced by words such as "anticipate," "expect," "plan," "could," "may," "will," "should," "would," "intend," "seem," "potential," "appear," "continue," "future," believe," "estimate," "forecast," "project," and similar words. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. We caution you, therefore, against relying on any of these forward-looking statements. Our actual results may differ materially from those contemplated by the forward-looking statements for a variety of reasons, including, without limitation, the risks arising from the impact of the COVID-19 pandemic on our Company, including supply chain disruptions, our continued ability to proceed with our programs, receive necessary regulatory approvals and continue to rely on certain third parties, and on the national and global economy, risks arising from our reliance on continuing collaboration with Merck under the collaboration agreement, the future results of preclinical and clinical studies, general risks arising from clinical trials, receipt of regulatory approvals, development of effective treatments and/or vaccines by competitors, and our ability to find and enter into agreements with suitable collaboration partners. Further information on the risk factors that could cause actual results to differ materially from those expressed or implied by forward-looking statements, is contained in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2019, as amended and supplemented by the Quarterly Reports on Form 10-Q for the three months ended June 30, 2020 and the three months ended September 30, 2020. Any forward-looking statement made by us in this presentation speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward- looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

2	cocrystalpharma.com

Cocrystal Drug Discovery Platform Technology

For Developing Broad Spectrum Antiviral Therapeutics

Drug target X-ray crystals

Drug pocket selection

Hit-to-lead process

Lead optimization

Drug candidates

3	cocrystalpharma.com

Traditional Drug Discovery and Development Process:

Slow Process and High Attrition Rate

• Target identification and target validation process required
• Compound screening and hit identification yield high attrition rate

Target	Target	HTS screening	Hit to Lead	Lead	Lead	Preclinical	Clinical trials
Identification	validation	discovery	optimization	lead

4	cocrystalpharma.com